NCT06326047

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Type 2 Diabetes - a Dose Finding Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 299 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	NNC0519-0130	NNC0519-0130 will be administered subcutaneously.
DRUG	Placebo	Placebo will be administered subcutaneously.
DRUG	Trizepatide	Trizepatide will be administered subcutaneously.

Timeline

• Start date: 2024-03-18
• Primary completion: 2025-09-19
• Completion: 2025-10-13
• First posted: 2024-03-22
• Last updated: 2025-12-31

Locations

94 sites across 7 countries: United States, Australia, Canada, India, Japan, South Africa, South Korea

Regulatory

• FDA-regulated drug study